News

Telix teams up with IBA-Framatome JV Ekalia on US astatine-211 production

What's the deal? Telix Pharmaceuticals, the Australian radiopharmaceutical company, announced on 19 October 2026 a collaboration with Ekalia — a joint venture between IBA and Framatome — to establish a dedicated US source of astatine-211, a scarce radioactive isotope being investigated for targeted alpha therapy (a treatment that delivers radiation directly to cancer cells).

What the collaboration involves: IBA's alpha-beam cyclotron technology and Framatome's nuclear expertise will be combined with Telix's US radiopharmacy network, starting with an installation at Telix's RLS Radiopharmacies site near Philadelphia. The framework secures long-term, priority astatine-211 access for Telix's alpha-therapy pipeline, including TLX102-Tx for glioblastoma (an aggressive brain cancer) and leptomeningeal disease, and will also supply third-party academic and industry programmes. The parties may add further installations at RLS sites as demand develops.

Why it matters: Astatine-211 is a promising alpha-emitting isotope for cancer treatment, but its broader use is constrained by limited production capacity. The collaboration extends to the US the European partnership IBA and Framatome formed to industrialise astatine-211 production, and gives Telix — which already runs a vertically integrated US diagnostics business built on its Illuccix, Gozellix and Pixclara imaging products — a path to owning the isotope supply for its emerging therapy pipeline.

Read more: Telix via PR Newswire, 19 October 2026

More top stories